MAPT and Alzheimer disease: Second, even when evaluating epigenetic signatures of AD CSF biomarkers among AD/MCI patients and controls, the most recent EWAS, which included 885 participants from the EMIF-AD study, also did not find strong evidence of an association for CSF amyloid measures and CSF tau variables, as no CpG sites passed the Bonferroni-significance threshold for those measures (22).